← SynDRA
DAPIPRAZOLE
SynDRA canonical compound SYN0023472 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · OTC |
| Primary target(s) | ADRA1A | ADRA1B | ADRA1D |
| Mechanism of action | adrenergic receptor antagonist |
| Indication | mydriasis |
| Disease area | ophthalmology |
All known targets
- ADRA1A
- ADRA1D
- ADRA1B
- ADRA2B
- Adra1a
- Adra1b
- DRD2
- HTR1A
- HTR2A
- HTR2B
- HTR2C
- Htr1a
Mechanisms of action (all sources)
- ADRA1A ANTAGONIST
- Alpha-1a adrenergic receptor antagonist
- ADRA1D ANTAGONIST
- adrenergic receptor antagonist
- DRD2 ANTAGONIST
Drug classes
- Adrenergic alpha-Antagonists
- alpha-Adrenergic Blocker
- Adrenergic Agents
- Adrenergic Antagonists
- Antipsychotic Agents
- Central Nervous System Agents
- Central Nervous System Depressants
- Neurotransmitter Agents
- Psychotropic Drugs
- Tranquilizing Agents
ATC classes
- S01E · ANTIGLAUCOMA PREPARATIONS AND MIOTICS
Cross-references
Synonyms
- dapiprazole hydrochloride
- AF-2139
- dapiprazole HCl
- Dapiprazol
- Dapiprazolum
- Dapirazol
- Dapirazolum
- Glamidolo
- Remydrial
- Reversil
- Dapiprazol [German]
- Dapiprazole [INN]
- Dapiprazole (INN)
- Dapirazol [INN-Spanish]
- Dapirazolum [INN-Latin]
- Rev-Eyes
- Rev-Eyes (TN)
- S-Triazolo(4,3-a)pyridine, 5,6,7,8-tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-,hydrochloride
- 3-(2-(4-(2-methylphenyl)-1-piperazinyl)ethyl)-5,6,7,8,-tetrahydro-1,2,4-triazolo(4,3-a)pyridine hydrochloride
- 3-[2-[4-(2-methylphenyl)piperazin-1-yl]ethyl]-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyridine
- 3-{2-[4-(2-methylphenyl)piperazin-1-yl]ethyl}-5,6,7,8-tetrahydro[1,2,4]triazolo[4,3-a]pyridine
- 5,6,7,8-Tetrahydro-3-(2-(4-(o-tolyl)-1-piperazinyl)ethyl)-s-triazolo(4,3-a)pyridine
- 5RNZ8GJO7K
- dapiprazolum
- CHEBI:51066
- dapiprazolo
- RefChem:57621
- DTXCID90145631
- S01EX02
- UNII-5RNZ8GJO7K
- DAPIPRAZOLE [MI]
- DAPIPRAZOLE [VANDF]
- DAPIPRAZOLE [WHO-DD]
- SCHEMBL152543
- GTPL7155
- orb1705094
- SCHEMBL29389682
- HY-A0142
Look up DAPIPRAZOLE in the interactive SynDRA portal →